Defunct Company
Total Trials
58
As Lead Sponsor
17
As Collaborator
41
Total Enrollment
6,545
NCT03157128
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Phase: Phase 1/2
Role: Collaborator
Start: May 2, 2017
Completion: Feb 28, 2027
NCT05338489
A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants
Phase: Phase 1
Start: May 11, 2018
Completion: Aug 22, 2018
NCT05468164
A Study of Effect of Food and a Proton Pump Inhibitor on Selpercatinib (LY3527723) in Healthy Participants
Start: May 31, 2018
Completion: Sep 13, 2018
NCT05338476
A Study of Effects of Selpercatinib (LY3527723) on Midazolam in Healthy Participants
Start: Jul 12, 2018
Completion: Sep 18, 2018
NCT05630287
A Study of Absorption, Metabolism, Excretion, and Absolute Bioavailability of Carbon-14-Labelled [14C] Selpercatinib (LY3527723) in Healthy Male Participants
Start: Aug 1, 2018
Completion: Sep 24, 2018
NCT05436912
A Study of Effects of Selpercatinib in Hepatically Impaired Participants and Healthy Participants
Start: Dec 10, 2018
Completion: Oct 30, 2019
NCT05469100
A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function
Start: Dec 19, 2018
Completion: Aug 7, 2019
NCT05469113
A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants
Start: Jan 29, 2019
Completion: Mar 5, 2019
NCT05338515
A Study of Selpercatinib (LY3527723) in Healthy Participants
Start: Feb 12, 2019
Completion: Mar 26, 2019
NCT03740529
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Role: Lead Sponsor
Start: Mar 15, 2019
Completion: Sep 30, 2027
NCT05630274
A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants
Start: Apr 16, 2019
Completion: Jun 21, 2019
NCT03899792
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
Start: Jun 13, 2019
Completion: May 31, 2029
NCT05338502
Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants
Start: Jul 8, 2019
Completion: Sep 3, 2019
NCT05134350
Study of the Effect of Food and a Proton Pump Inhibitor (PPI; Omeprazole) on LOXO-305 in Healthy Participants
Start: Feb 6, 2020
Completion: Mar 23, 2020
NCT04211337
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Phase: Phase 3
Start: Feb 11, 2020
Completion: Feb 28, 2026
NCT05134337
Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants
Start: Feb 12, 2020
Completion: Oct 30, 2020
NCT04194944
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Start: Feb 17, 2020
Completion: Jun 30, 2030
NCT06181006
A Study to Evaluate Pirtobrutinib (LOXO-305) in Healthy Adult Participants
Start: Aug 14, 2020
Completion: Dec 1, 2020
NCT06180967
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Different Formulations of Midazolam in Healthy Participants
Start: Sep 3, 2020
Completion: Oct 20, 2020
NCT06180954
A Study of Carbon-14-Labelled [14C] LOXO-305 (Pirtobrutinib) in Healthy Male Participants
Start: Sep 23, 2020
Completion: Nov 6, 2020
NCT06165146
A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy Participants
Start: Nov 10, 2020
Completion: Dec 30, 2020
NCT06215521
A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants
Start: Dec 15, 2020
Completion: Mar 31, 2021
NCT06190691
Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants
Start: Dec 18, 2020
Completion: Dec 30, 2021
NCT06180980
A Study of the Effect of Food on Pirtobrutinib (LOXO-305) in Healthy Participants
Start: Jan 4, 2021
Completion: Mar 8, 2021
NCT06215430
A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants
Start: Jan 11, 2021
Completion: Apr 15, 2021
NCT06190678
Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy Participants
Start: Feb 1, 2021
Completion: Jun 4, 2021
NCT06181045
A Study of LY3410738 in Healthy Adult Participants
Start: Feb 24, 2021
Completion: Aug 4, 2021
NCT04782076
A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants
Start: Mar 5, 2021
Completion: May 17, 2021
NCT04666038
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Start: Mar 9, 2021
Completion: May 31, 2027
NCT06194214
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants
Start: Mar 11, 2021
Completion: Jun 9, 2021
NCT04662255
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
Start: Apr 8, 2021
Completion: Apr 30, 2028
NCT04849416
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
Phase: Phase 2
Start: May 14, 2021
Completion: Dec 31, 2025
NCT04965493
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Start: Sep 20, 2021
Completion: Jan 31, 2027
NCT05023980
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Start: Sep 23, 2021
Completion: Aug 31, 2026
NCT06258174
A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy Participants
Start: Sep 28, 2021
Completion: Dec 22, 2021
NCT06181084
A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants
Start: Oct 11, 2021
Completion: Apr 28, 2022
NCT05089019
A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants
Start: Oct 29, 2021
Completion: Jul 19, 2022
NCT05136404
A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants
Start: Dec 3, 2021
Completion: Mar 14, 2022
NCT04819100
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
Start: Dec 20, 2021
Completion: May 31, 2028
NCT05205447
Study of the Effects of Itraconazole and Carbamazepine on LY3410738 in Healthy Participants
Start: Jan 5, 2022
Completion: Apr 12, 2022
NCT05176314
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants
Start: Jan 11, 2022
Completion: Apr 20, 2022
NCT05324124
A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants
Start: Apr 19, 2022
Completion: Jun 22, 2022
NCT05254743
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Start: Jul 22, 2022
Completion: Jan 31, 2028
NCT05536349
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
Start: Dec 20, 2022
Completion: Apr 25, 2028
NCT05529069
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
Start: Jan 25, 2023
Completion: Apr 28, 2027
NCT05824858
A Study of the Effect of Food on LY3537982 in Healthy Participants
Start: Apr 12, 2023
Completion: Jun 17, 2023
NCT05860933
A Study of the Effects of Itraconazole or Carbamazepine on LY3537982 in Healthy Participants
Start: May 8, 2023
Completion: Aug 28, 2023
NCT05901311
A Study of [14C]-LY3537982 in Healthy Participants
Start: Jun 5, 2023
Completion: Aug 10, 2023
NCT05894928
A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants
Start: Jun 7, 2023
Completion: Jul 9, 2023
NCT06028425
A Study to Evaluate the Effect of Food on LOXO-783 in Healthy Participants
Start: Sep 1, 2023
Completion: Dec 23, 2023
NCT06102512
A Study of [14C]-LOXO-783 in Healthy Adult Participants
Start: Oct 23, 2023
Completion: Jan 17, 2024
NCT06111521
A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants
Start: Oct 27, 2023
Completion: Apr 1, 2024
NCT06043674
A Ph2 Study of Glofitamab Alone or With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Start: Jan 22, 2024
Completion: Jan 15, 2033
NCT06333262
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
Start: Apr 22, 2024
Completion: Feb 1, 2029
NCT06104683
A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis
Start: May 1, 2024
Completion: Feb 13, 2026
NCT06588478
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Start: Jan 3, 2025
Completion: Dec 31, 2028